RxDoctor Payments Data

Melanie Sheen, MD

Hematology & Oncology · Tampa, FLNPI 1366767329

Payments from drug & device makers

$431,682in general payments, 2019–2025

Across 194 payments — averaging $2225.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$197K
  • AstraZeneca$114K
  • Daiichi Sankyo Inc.$37K
  • Merck$35K
  • Gilead$26K
  • Stemline Therapeutics Inc.$12K
  • plus $10K from 19 others
$5,467in research payments, 2019–2025

Across 2 payments — averaging $2733.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$5K

What the payments were for

  • Consulting fees$23,76619%
  • Speaking & faculty fees$92,74074%
  • Travel & lodging$2,0452%
  • Food & beverage$6,3445%
  • Education$1430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$431,682 in reported general payments places this provider in the 75th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$45,138
Medicare patients
179
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib33$517,761
KisqaliRibociclib Succinate16$273,376
VerzenioAbemaciclib13$185,417
EliquisApixaban58$42,043
Anastrozole573$8,563
Exemestane32$3,383
Letrozole125$2,374
Tamoxifen Citrate64$1,241
Venlafaxine Hcl ErVenlafaxine Hcl33$500
Oxycodone Hcl21$457
Dexamethasone18$396
Gabapentin39$314
Hydroxyurea13$227
Alendronate Sodium16$151
Potassium Chloride11$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali$4,574$273,37616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →